Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.75 USD
+0.29 (8.38%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.76 +0.01 (0.27%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.75 USD
+0.29 (8.38%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $3.76 +0.01 (0.27%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Zacks News
Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View
by Zacks Equity Research
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22
by Zacks Equity Research
Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.
Roche's (RHHBY) Cancer Drug Glofitamab Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.
Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes
by Zacks Equity Research
Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.
AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers
by Zacks Equity Research
The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.
Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.
Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag
by Zacks Equity Research
Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.
Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data
by Zacks Equity Research
Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.
Repare Therapeutics Inc. (RPTX) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale
by Zacks Equity Research
bluebird (BLUE) is set to sell one of its two priority review vouchers. This will strengthen its financial position as its existing cash balance is expected to exhaust by second-quarter 2023.
How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 95%
by Zacks Equity Research
The consensus price target hints at a 95.5% upside potential for Repare Therapeutics Inc. (RPTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Repare Therapeutics Inc. (RPTX) Climb 106% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 106.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Repare Therapeutics Inc. (RPTX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 955% and 160.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BeiGene, Ltd. (BGNE) Soars 20.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -5.81% and 68.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -20.69% and 79.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Biotech ETF Tops in June: 5 Stocks That Outperform
by Sweta Killa
Virtus LifeSci Biotech Clinical Trials ETF (BBC) topped the list of the best-performing U.S. equity ETFs in June, gaining about 10%. The rally was driven by traders' "short squeeze" and investors' bargain hunting.
Repare (RPTX) Up 20% on Deal With Roche for Solid Tumor Drug
by Zacks Equity Research
Repare Therapeutics (RPTX) signs a licensing agreement with Roche (RHHBY) to develop its lead candidate for solid tumor indications.
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Global Blood Therapeutics (GBT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Stock Jumps 9.1%: Will It Continue to Soar?
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.67% and 94.54%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -60% and 84.19%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -18.57% and 39.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Repare Therapeutics (RPTX)
by Zacks Equity Research
Repare Therapeutics (RPTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.